Novo Nordisk will pay $300 million upfront, and up to $2.6 billion in total, for Hengrui's once-weekly GLP-1/GIP pill, which has not been tested in people. North Carolina Budget Sends Over $10.7 ...
Are we seeing the signs and symptoms of ADHD clearly? A 2024 report from the Centers for Disease Control and Prevention revealed a staggering uptick in ADHD diagnoses among American children. But many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results